Teva’s Acquisition Of Barr Will Boost Research For Molecules Large And Small

Teva expects to double its R&D capabilities with the acquisition of Barr, executives from both firms said during a July 21 luncheon in New York

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet